Patient's global assessment of disease activity: What are we measuring?

The author highlights growing interest of patient reported outcome's use in rheumatoid arthritis (RA) clinical trials and in clinical practice. He discusses several studies that determine differences between patient's and physician's assessments of disease activity, and factors that influence the two measures. It also highlights that a patient's global assessment of ≤1 on a scale of 0-10 is needed as per Boolean remission criteria of the new The American College of Rheumatology (ACR/EULAR).